Person:
YUMUK, PERRAN FULDEN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

YUMUK

First Name

PERRAN FULDEN

Name

Filters

2004 - 20064
Reset filters

Settings

End date: 2009 × Has files: true ×

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    PublicationOpen Access
    D-dimer - Can it be a marker for malignant gastric lesions?
    (TAYLOR & FRANCIS LTD, 2004-12) YUMUK, PERRAN FULDEN; Aliustaoglu, M; Yumuk, PF; Gumus, M; Ekenel, M; Bolukbas, F; Bolukbas, C; Mutlu, N; Basaran, G; Avsar, E; Turhal, NS
  • Thumbnail Image
    PublicationOpen Access
    Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer
    (BMC, 2005-12) YUMUK, PERRAN FULDEN; Abacioglu, U; Yumuk, PF; Caglar, H; Sengoz, M; Turhal, NS
    Background: Combined chemoradiotherapy (CRT) is the treatment of choice for stage III NSCLC. Gemcitabine (G) is a novel deoxycitidine analogue that has been proven to be a potent radiosensitizer. Twenty-two consecutive patients were treated with concurrent CRT to demonstrate the tolerability and efficacy of low dose G given weekly as radiosensitizer in stage III NSCLC. Methods: Patients with KPS >= 70, adequate bone marrow reserve, with no prior radiotherapy (RT) and surgery were included. Eighteen patients had received prior induction chemotherapy (CT). G (75 mg/m(2)/week) was infused over 1 hour for 6 weeks. Thoracic RT was given two hours later over 6 weeks at 1.8 Gy/day fractions (total dose of 61.2 Gy). Pulmonary toxicity was evaluated with computed tomography scans in 6 weeks. Results: Median age was 60 years (range, 48-75), median follow-up was 15 months (range, 2-40). Sixty-eight percent of patients were male and median KPS score was 90. Conformal 3D-RT planning was used in 64% of patients. G was given for a median of 5 weeks ( range 1-9). Twelve patients (54.6%) received all planned CT. G was stopped because of intolerance in 6 and death in 2 patients. Seven patients (31.8%) had radiation pneumonitis. Twenty patients were evaluated for overall response, 1 patient (4.5%) had clinical CR, 81.8% had PR while 9.5% had SD. Median overall survival (OS) was 14 +/- 5 months (95% CI 3-25). One- and 2-year OS rates were 55% and 38%. Sixteen patients died of disease-related events (6 with progression of primary tumor, 8 due to metastatic disease), 2 patients died of other causes. One- and 2-year progression- free survival and local control rates were 56%, 27% and 79%, 51%, respectively. Conclusion: G might be used as radiosensitizer for patients with stage III NSCLC who could not receive full doses CT with concurrent RT.
  • Thumbnail Image
    PublicationOpen Access
    Interstitial pneumonitis associated with docetaxel administration
    (OXFORD UNIV PRESS, 2006-09) CEYHAN, BERRİN; Dane, Faysal; Topaloglu, Nurhayat; Abul, Yasin; Yumuk, Perran F.; Turhal, Nazim S.; Ceyhan, Berrin; Celikel, Turgay; Caglar, Hale; Basaran, Gul; Ahiskali, Rengin
  • Thumbnail Image
    PublicationOpen Access
    Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer
    (BMC, 2005-12) YUMUK, PERRAN FULDEN; Yumuk, PF; Turhal, NS; Gumus, M; Hatabay, NF; Turken, O; Ozkan, A; Salepci, T; Aliustaoglu, M; Ahiskali, R
    Background: Both paclitaxel ( P) and carboplatin ( C) have significant activity in non-small cell lung cancer (NSCLC). The weekly administration of P is active, dose intense, and has a favorable toxicity profile. We retrospectively reviewed the data of 51 consecutive patients receiving C and day 1 and 8 P chemotherapy (CT) regimen in advanced stage NSCLC to evaluate the efficacy and toxicity. Methods: Patients treated in our institutions having pathologically proven NSCLC, no CNS metastases, adequate organ function and performance status (PS) ECOG 0-2 were given P 112.5 mg/m(2) intravenously (IV) over 1 hour on day 1 and 8, followed by C AUC 5 IV over 1 hour, repeated in every three weeks. PC was given for maximum of 6 cycles. Results: Median age was 58 ( age range 39-77) and 41 patients (80%) were male. PS was 0/1/2 in 29/17/5 patients and stage was IIIA/IIIB/IV in 3/14/34 patients respectively. The median number of cycles administered was 3 ( 1 6). Seven patients (14%) did not complete the first 3 cycles either due to death, progression, grade 3 hypersensitivity reactions to P or lost to follow up. Best evaluable response was partial response (PR) in 45% and stable disease (SD) in 18%. Twelve patients (24%) received local RT. Thirteen patients (25%) received 2nd line CT at progression. At a median follow-up of 7 months (range, 1-20), 25 (49%) patients died and 35 patients (69%) progressed. Median overall survival ( OS) was 11 +/- 2 months (95% CI; 6 to 16), 1-year OS ratio was 44%. Median time to progression (TTP) was 6 +/- 1 months (95% CI; 4 to 8), 1-year progression free survival (PFS) ratio was 20%. We observed following grade 3 toxicities: asthenia (10%), neuropathy (4%), anorexia (4%), anemia (4%), hypersensitivity to P (2%), nausea/vomiting (2%), diarrhea ( 2%) and neutropenia (2%). Two patients (4%) died of febrile neutropenia. Doses of CT were reduced or delayed in 12 patients (24%). Conclusions: P on day 1 and 8 and C every three weeks is practical and fairly well tolerated outpatient regimen. This regimen seems to be comparably active to regimens given once in every three weeks.